BTI
The upgrade hangover
British American Tobacco is back in the “show me” camp. The stock was downgraded from Buy to Hold after a look under the hood showed the usual problem: the old engines are sputtering, and the shiny new ones aren’t revving fast enough to matter.
What’s going wrong?
The core issue is pretty simple, if not exactly fun:
- revenue is still slipping
- volumes are falling across major regions
- combustibles are under pressure
- traditional oral products are also losing steam
That’s not the kind of cocktail investors usually toast to. When your legacy businesses are shrinking and your replacement products are only partially filling the gap, the market tends to start asking annoying questions like, “Okay, but what’s the next leg of growth?”
The Velo problem
Modern oral products — especially Velo — are still the bright spot in the story. But this is one of those situations where the good news is real, just not real enough.
Think of it like a house with one room getting renovated while the rest of the place still has plumbing issues. Nice progress, sure. But you’re not exactly moving in tomorrow.
Big picture
For BTI, this downgrade is a reminder that investors are paying for a turnaround story that still needs more proof. If the company can’t stabilize volumes and turn modern oral into a bigger growth engine, upside gets capped fast. The market loves a comeback — but it loves actual evidence even more.